3results about How to "Responsiveness" patented technology

This invention relates to a hypoxia-responsive T2-T1 switchable MRI contrast agent, its preparation method, and its application. The hypoxia-responsive T2-T1 switchable MRI contrast agent comprises iron oxide nanoclusters and polyethylene glycolamine and / or ethanolamine modified on the iron oxide nanoclusters. The iron oxide nanoclusters are obtained by cross-linking iron oxide nanoparticles via hypoxia-sensitive azo bonds. The MRI contrast agent of this invention can specifically respond to the hypoxia environment of the tumor microenvironment, thereby achieving a change from aggregation to dispersion of extremely small iron oxide nanoclusters, thus enabling the switching from T2-type to T1-type contrast signals. Furthermore, after dissociation in response to the hypoxia environment, the re-formed extremely small iron oxide nanoparticles are more readily metabolized, increasing biocompatibility.

This invention relates to a hydrogen-bonded organic framework material with thermal exciton properties, its preparation method, and its applications. The material utilizes organic ligands with aggregation-induced emission properties, forming a three-dimensional periodic network through intermolecular hydrogen bond self-assembly. The ordered molecular stacking within the framework effectively activates and enhances the intrinsic luminescence performance of the ligands. Furthermore, by introducing halogen atoms for structural modulation, the excited-state energy levels can be finely tuned, thereby inducing thermal exciton properties and significantly improving the utilization efficiency of triplet excitons. This material possesses rapid luminescence kinetics and holds promise as a high-performance scintillator. Its high triplet state utilization efficiency significantly enhances its light yield, reaching 14474 MeV. ‑1 Furthermore, this material can be incorporated into a polymer matrix to form flexible thin films, exhibiting excellent X-ray imaging capabilities.

This invention discloses a class of tumor-targeting prodrug compounds that synergistically enhance photodynamic / chemotherapy through azoreductase activation, their preparation method, and their application in selectively killing cancer cells and treating tumors. The first objective is to provide a class of tumor-targeting prodrug compounds that synergistically enhance photodynamic / chemotherapy through azoreductase activation. These compounds possess the properties of positively charged cyanine dyes, allowing them to target tumor sites and localize to the mitochondria of cancer cells to a certain extent. Through simultaneous activation of azoreductase, photosensitizers and chemotherapeutic drugs are released, achieving selective killing of cancer cells and targeted tumor therapy. The second objective is to provide a method for preparing the prodrug compound. In an anhydrous system, an indole compound containing an R1 group and modified with different substituents at the benzene ring position is reacted with 2-chloro-3-(hydroxymethylene)-1-cyclohexene-1-carboxaldehyde to obtain compound IV. Then, compound IV is reacted with m-nitrophenol and reduced to obtain compound V. Finally, compound V undergoes a diazotization reaction with sodium nitrite, and a compound containing an R2 group is added to continue the reaction to obtain the target prodrug compound.